• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

IV alteplase improves functional outcomes in patients with stroke of unknown onset

byVineeth BhogadiandTeddy Guo
December 8, 2020
in Emergency, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients who had a stroke with unknown time of onset and DWI-FLAIR or perfusion mismatch, IV alteplase resulted in better functional outcomes at 90 days compared to placebo or current standard care.

2. The prevalence of severe disability or death was lower with IV alteplase, but was also associated with increased risk of symptomatic intracranial hemorrhage and higher mortality.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Thrombolysis with intravenous alteplase is the current standard of care for acute ischemic stroke. Treatment with alteplase has traditionally been reserved for patients with known time of symptom onset, but in approximately 20-25% of patients with stroke, time of symptom onset is unknown. However, several individual trials utilizing imaging biomarkers to select patients with unknown time of stroke onset for IV thrombolysis have shown promise with net clinical benefit. This systematic review and meta-analysis included individual patient data from four randomized-controlled trials comparing IV alteplase with placebo or standard of care in adults with stroke of unknown time of onset. Patients were selected using imaging biomarkers (MRI diffusion weighted imaging-fluid attenuated inversion recovery [DWI-FLAIR] mismatch or perfusion CT/MRI based penumbral imaging) to help identify salvageable tissue. Treatment with alteplase was associated with significantly improved functional outcomes including functional independence at 90 days compared to control. Additionally, a net benefit across all functional outcomes was observed with thrombolysis despite an increased risk of symptomatic intracranial hemorrhage and higher mortality. Prevalence of severe disability or death was lower with IV alteplase. This study was limited by the overall small number of patients included in the meta-analysis allowing for limited conclusions to be drawn from sub-group analysis. Additionally, the conclusions of this meta-analysis may be driven by the results of the WAKE-UP trial which represented most patients included in the analysis.

Click to read the study in The Lancet

Relevant Reading: MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

In-Depth [systematic review]: This systematic review and meta-analysis included individual patient data from four randomized-controlled trials comparing IV alteplase with placebo or standard of care in adults with stroke of unknown time of onset and imaging mismatch (perfusion-diffusion MRI, perfusion CT or MRI with DWI-FLAIR). The primary outcome was defined as a favourable score of 0-1 on the modified Rankin Scale (mRS) to identify patients with no symptoms or minimal symptoms with no functional disability at 90 days after stroke.

RELATED REPORTS

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Endovascular therapy for large ischemic strokes provides better functional outcomes

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

A total of four trials met the inclusion criteria with individual patient data for 843 patients (mean age = 68.5 years; 38% female) included in the analysis. Overall, a favorable outcome (mRS score 0-1) at 90 days was observed in 199 of 420 (47%) patients in the alteplase group and in 160 of 409 (39%) patients in the control group (adjusted odds ratio [OR] 1.49, 95% CI 1.10 to 2.03; p=0.011) with low heterogeneity across studies (I2=27%). Alteplase treatment was associated with improved functional outcomes with lower mRS scores (adjusted common OR 1.38, 95% CI 1.05 to 1.80; p=0.019) and increased proportion of patients who reached functional independence (mRS score 0-2) at 90 days (adjusted OR 1.50, 95% CI 1.06 to 2.12; p=0.022) compared to control. In the alteplase group, 21% of patients were severely disabled or died (mRS score 4-6) compared to 25% of patients in the control group (adjusted OR 0.76, 95% CI 0.52 to 1.11; p=0.14). However, overall, 6% of patients died in the alteplase group compared to 3% among controls (adjusted OR 2.06, 95% CI 1.03 to 4.09; p=0.040) Patients receiving alteplase had a higher overall prevalence of symptomatic intracranial hemorrhage compared to controls (3% vs <1%, adjusted OR 5.58, 95% CI 1.22 to 25.50; p=0.024). Overall, study findings suggest that IV alteplase in patients with a stroke of unknown time of onset (with a DWI-FLAIR or perfusion mismatch) is associated with improved functional outcomes and functional independence.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alteplaseischemic strokestrokethrombolysis
Previous Post

Consumption of red meat associated with elevated risk of coronary heart disease

Next Post

#VisualAbstract: Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Patient Basics: Stroke Overview
Emergency

Endovascular therapy for large ischemic strokes provides better functional outcomes

April 22, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Combined MRI and NIH stroke scores may predict stroke prognosis
Emergency

Large vessel occlusion stroke is associated with poor prognosis in children

March 29, 2022
Next Post
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure

#VisualAbstract: Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Behavioral dysregulation in infancy predicts later child mental health

Hyoscine butylbromide and acetaminophen have comparable effects for pediatric non-specific colicky abdominal pain

1 in 5 US women report delayed contraceptive initiation after sexual debut

Improved contraception use with progestogen-only pill and rapid access vs emergency contraception

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.